Viking Therapeutics, Inc.
VKTXNasdaq
$37.08
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↑ +17.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.3B
Enterprise Value
$3.7B
P/E
—
P/S
—
P/B
8.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$472.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-94.1%
ROIC
—
Debt / Equity
—
Net Cash
$603.0M
Return 1Y
+15.6%
Company profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
- CEO
- Brian Lian
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- vikingtherapeutics.com
Management & directors
- Aubuchon Neil WilliamChief Commercial Officer
- Lian BrianPresident & CEO
- Mancini MariannaChief Operating Officer
- Zante GregChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
VKTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$1.37↑ +234.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$42.7M | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| Net income | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| Diluted EPS | — | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
| Operating cash flow | -$21.8M | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$34.1M | -$36.6M | -$46.2M | -$55.5M | -$74.6M | -$98.6M | -$164.7M | -$164.1M |
| Net income | -$22.3M | -$24.9M | -$35.4M | -$45.6M | -$65.6M | -$90.8M | -$157.7M | -$158.3M |
| Diluted EPS | -$0.20 | -$0.22 | -$0.33 | -$0.41 | -$0.58 | -$0.81 | -$1.39 | -$1.37 |
| Operating cash flow | -$28.5M | -$22.0M | -$31.2M | -$52.3M | -$47.1M | -$94.0M | -$85.3M | -$114.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 18, 2026
Jul 17, 2026
- 3d agoViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Notefinance.yahoo.com
- 3d agoViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?finance.yahoo.com
- 3d agoThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Ideafinance.yahoo.com
Jul 16, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-10 | Aubuchon Neil William· Chief Commercial Officer | Buy | 4,475 | $33.50 | $149,912.50 | filing |
| 2026-01-05 | Lian Brian· President & CEO | Sale | 132,454 | $32.29 | $4.3M | filing |
| 2026-01-05 | Lian Brian· President & CEO | Sale | 53,279 | $33.38 | $1.8M | filing |
| 2026-01-05 | Lian Brian· President & CEO | Sale | 41,276 | $34.22 | $1.4M | filing |
| 2026-01-05 | ZANTE GREG· Chief Financial Officer | Sale | 31,961 | $32.30 | $1.0M | filing |
| 2026-01-05 | Mancini Marianna· Chief Operating Officer | Sale | 31,961 | $32.29 | $1.0M | filing |
| 2026-01-05 | ZANTE GREG· Chief Financial Officer | Sale | 13,900 | $33.38 | $464,020.92 | filing |
| 2026-01-05 | Mancini Marianna· Chief Operating Officer | Sale | 13,600 | $33.37 | $453,875.52 | filing |
| 2026-01-05 | Mancini Marianna· Chief Operating Officer | Sale | 10,500 | $34.22 | $359,302.65 | filing |
| 2026-01-05 | ZANTE GREG· Chief Financial Officer | Sale | 10,300 | $34.24 | $352,634.92 | filing |
| 2026-01-05 | Lian Brian· President & CEO | Sale | 6,400 | $35.07 | $224,423.04 | filing |
| 2026-01-05 | Mancini Marianna· Chief Operating Officer | Sale | 1,600 | $35.07 | $56,116.96 | filing |
| 2026-01-05 | ZANTE GREG· Chief Financial Officer | Sale | 1,500 | $32.09 | $48,133.05 | filing |
| 2026-01-02 | FOEHR MATTHEW W | Sale | 16,000 | $35.11 | $561,694.40 | filing |
| 2026-01-02 | FOEHR MATTHEW W | Option exercise | 16,000 | $3.33 | $53,280.00 | filing |
| 2026-01-02 | Rouan Sarah Kathryn | Award | 3,150 | $0.00 | $0.00 | filing |
| 2026-01-02 | ZANTE GREG· Chief Financial Officer | Award | 41,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | ZANTE GREG· Chief Financial Officer | Award | 32,049 | $0.00 | $0.00 | filing |
| 2026-01-02 | Mancini Marianna· Chief Operating Officer | Award | 41,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Mancini Marianna· Chief Operating Officer | Award | 32,049 | $0.00 | $0.00 | filing |
| 2026-01-02 | Lian Brian· President & CEO | Award | 78,400 | $0.00 | $0.00 | filing |
| 2026-01-02 | Lian Brian· President & CEO | Award | 224,080 | $0.00 | $0.00 | filing |
| 2026-01-02 | SINGLETON J MATTHEW | Award | 3,150 | $0.00 | $0.00 | filing |
| 2026-01-02 | MACARTNEY LAWSON | Award | 3,150 | $0.00 | $0.00 | filing |
| 2026-01-02 | Rowland Charles A Jr | Award | 3,150 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.